Omeros Corporation Reports Q3 2026 Sales Momentum for YARTEMLEA and Projects Discontinued Operations Income
Omeros Corporation (OMER) reported strong commercial performance for its product YARTEMLEA in the third quarter of 2026. According to CEO Gregory Demopulos, the product generated $41.8 million in gross sales and $35.9 million in net sales, signaling sustained market momentum as the company expands outpatient use and educational initiatives. Looking ahead to the fourth quarter of 2026, Omeros expects income from discontinued operations to range between $5 million and $6 million. The company remains focused on scaling its commercial footprint for YARTEMLEA while managing its transition through various operational phases.

Tickers: $OMER
Topics: earnings revenue sales growth